Tag: obesity
-
Genentech Bets $2.3 Billion on Hanmi’s Muscle-Preserving Obesity Drug
Genentech licensed Hanmi’s HM17321 in a deal worth up to $2.3 billion, adding a non-incretin obesity candidate designed to reduce fat while preserving muscle.
-
How HM17321 Could Preserve Muscle During Weight Loss
HM17321 uses UCN2–CRFR2 signaling to target fat loss and muscle preservation through a non-incretin mechanism, offering a different approach to obesity treatment.
-
Novo Nordisk’s Wegovy Shows Liver-Health Benefits Beyond Weight Loss in MASH Patients
Novo Nordisk’s once-weekly semaglutide 2.4 mg (Wegovy) demonstrated remarkable liver-health improvements in metabolic dysfunction-associated steatohepatitis (MASH) patients—even those with minimal weight loss—signalling a potential paradigm shift in the obesity-related liver-disease market.